About: Gatifloxacin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gatifloxacin Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar®. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. [Wikipedia] (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B58FE-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B58FF-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM: Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006 Mar 30;354(13):1352-61. Epub 2006 Mar 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16510739 # Gurwitz JH: Serious adverse drug effects--seeing the trees through the forest. N Engl J Med. 2006 Mar 30;354(13):1413-5. Epub 2006 Mar 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16510740 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	7-14 hours (en)
http://linked.open...ugbank/indication	For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes (en)
sameAs	Gatifloxacin
Title	Gatifloxacin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/chebi/5280 http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/chemspider/5186 http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/drugbank/DB01044 http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/kegg-compound/C07661 http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/national-drug-code-directory/0023-9218-05 http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/pharmgkb/PA449738 http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/pubchem-compound/5379 http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/pubchem-substance/46506159 http://linked.opendata.cz/resource/drugbank/drug/DB01044/identifier/wikipedia/Gatifloxacin
http://linked.open...mechanismOfAction	The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. (en)
http://linked.open...drugbank/packager	Allergan Inc. AQ Pharmaceuticals Inc. Bristol-Myers Squibb Co. Cardinal Health Lake Erie Medical and Surgical Supply Mead Johnson and Co. PD-Rx Pharmaceuticals Inc.
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/1340316 http://linked.opendata.cz/resource/drugbank/patent/2307632 http://linked.opendata.cz/resource/drugbank/patent/4980470 http://linked.opendata.cz/resource/drugbank/patent/6333045
http://linked.open.../drugbank/synonym	1-Cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid (en) AM 1155 (en) Gatifloxacine (en) Gatifloxacino (en) Gatifloxacinum (en) 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/52-04-04
http://linked.open...k/foodInteraction	Drink liberally. (en) Take without regard to meals. (en) Absorption does not seem to be affected by milk or calcium carbonate, however, gatifloxacin bioavailability appears significantly reduced when combined with Ensure™ (C<sub>max</sub> is reduced by about 50% while total drug exposure (AUC) is reduced by about 25%). (en)
http://linked.open...nk/proteinBinding	20% (en)
http://linked.open...ynthesisReference	"DrugSyn.org":http://www.drugsyn.org/Gatifloxacin.htm (en)
foaf:page	http://www.drugs.com/cdi/gatifloxacin-drops.html http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/zym1676.shtml http://www.rxlist.com/cgi/generic3/gatifloxacin.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5904-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B590A-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5909-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5906-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5907-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B5908-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B591A-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5902-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B591C-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5900-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5903-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B5901-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Gatifloxacin Gatifloxacin
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5910-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5911-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B590B-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B590C-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B590E-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B590D-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B590F-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Well absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96% (en)
http://linked.open.../affectedOrganism	Enteric bacteria and other eubacteria (en) Mycobacterium (en) Chlamydia pneumoniae (en) Chlamydia trachomatis (en) Legionella pneumophila (en) Mycoplasma pneumoniae (en) Chlamydia psittaci (en)
http://linked.open...casRegistryNumber	112811-59-3 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...gbank/containedIn	Erythromycin Base 250 mg tablet E-mycin 333 mg tablet ec
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B5916-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B5918-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B5919-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B591B-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5915-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5914-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B5917-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5905-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B5912-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B5913-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software